Results 61 to 70 of about 22,402 (256)

Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry

European Journal of Haematology, 2022
The effects of eculizumab treatment in paroxysmal nocturnal hemoglobinuria (PNH) patients with or without high‐disease activity (HDA), defined by LDH ≥ 1.5 × ULN and history of major adverse vascular events (MAVEs; including thrombotic events [TEs ...
B. Höchsmann, F. Sicre de Fontbrune, J. W. Lee, A. Kulagin, P. Hillmen, A. Wilson, J. Marantz, H. Schrezenmeier   +7 more
semanticscholar   +1 more source

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria

eJHaem
Background Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single‐arm phase 3 APPOINT‐PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor‐naive ...
Matthew Holt, Richard J. Kelly, Jilles M. Fermont, Soudeh Ansari, Marion Dahlke, Isabelle Brindel, Lynda Maafa, Flore Sicre deFontbrune, Régis Peffault deLatour   +8 more
doaj   +1 more source

Primaquine-induced hemoglobinuria: a case report of a G6PD deficient malaria patient with Mahidol trait from Bandarban, Bangladesh

Frontiers in Malaria
We report a case of Primaquine (PQ) induced hemoglobinuria in a patient with the glucose-6-phosphate dehydrogenase (G6PD) Mahidol variant from Bandarban, Bangladesh.
Md Fahad Zamil, Ching Swe Phru, Anamul Hasan, Afrida Tabassum Trina, Mohammad Shahbaz, Shahrear Tanvir Ahmed, Mohammad Sharif Hossain, Mohammad Shafiul Alam   +7 more
doaj   +1 more source

Sequential catalytic nanosystem of carbon dots and uricase integrated with polydopamine for therapy of gouty wound ulceration

BMEMat, EarlyView.
Sequential dual‐catalytic treatment of the gout wound ulceration process by CDs‐Uri@PDA. (a) Synthesis steps and morphology of CDs‐Uri@PDA. (b) Sequential treatment process and mechanism of CDs‐Uri@PDA for gout wound ulceration according to (i) uric acid reduction, (ii) antibacterial activity, and (iii) anti‐inflammatory effects.
Yonglan Yang, Yang Yang, Pengpeng Ma, Ruiqi Zhu, Xia Pan, Shaoling Zheng, Bo Chen, Yanli Jin, Youcong Gong, Jie Liu, Tianwang Li, Xu Chen   +11 more
wiley   +1 more source

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Blood, 2020
Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are pathogenically related non-malignant bone marrow failure disorders linked to T-cell mediated autoimmunity and associated with an increased risk of secondary myelodysplastic ...
Lova Sun, D. Babushok
semanticscholar   +1 more source

Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats

Haematologica, 2009
Background The presence of paroxysmal nocturnal hemoglobinuria clones in the setting of aplastic anemia or myelodysplastic syndrome has been shown to have prognostic and therapeutic implications. However, the status of paroxysmal nocturnal hemoglobinuria
Sa A. Wang, Olga Pozdnyakova, Jeffrey L. Jorgensen, L. Jeffrey Medeiros, Dariusz Stachurski, Mary Anderson, Azra Raza, Bruce A. Woda   +7 more
doaj   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy

International Journal of Laboratory Hematology
Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti‐C5 monoclonal antibody eculizumab was the first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at the price of a life ...
Francesco Versino, B. Fattizzo
semanticscholar   +1 more source

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Haematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
R. Brodsky, R. D. de Latour, S. Rottinghaus, A. Röth, A. Risitano, I. Weitz, P. Hillmen, J. Maciejewski, J. Szer, J. W. Lee, A. Kulasekararaj, L. Volles, A. Damokosh, S. Ortiz, L. Shafner, Peng Liu, A. Hill, H. Schrezenmeier   +17 more
semanticscholar   +1 more source

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety

Research and Practice in Thrombosis and Haemostasis, 2022
Pegcetacoplan, a pegylated penta‐decapeptide, targets complement C3 to control both intravascular and extravascular hemolysis. This systematic review aims to study the efficacy and safety of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH).
Sangam Shah, Rajan Chamlagain, Ziyaul Haq Musalman, Yagya Raj Adhikari, S. Chhetri, Sujan Paudel, Krishna Gundabolu, P. Dhakal   +7 more
semanticscholar   +1 more source